Treatment of Functional Dyspepsia in Outpatients after COVID-19 Infection
Aim: to compare the efficacy of different therapeutic regimens for managing functional dyspepsia in outpatients after COVID-19 infection.Materials and methods. 42 post-COVID-19 outpatients (age: 26–47 years) diagnosed with functional dyspepsia (FD) according to the Rome IV Criteria were enrolled in...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2023-05-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/780 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860077967179776 |
|---|---|
| author | M. S. Turchina Yu. M. Morozov T. I. Obolenskaya |
| author_facet | M. S. Turchina Yu. M. Morozov T. I. Obolenskaya |
| author_sort | M. S. Turchina |
| collection | DOAJ |
| description | Aim: to compare the efficacy of different therapeutic regimens for managing functional dyspepsia in outpatients after COVID-19 infection.Materials and methods. 42 post-COVID-19 outpatients (age: 26–47 years) diagnosed with functional dyspepsia (FD) according to the Rome IV Criteria were enrolled in two parallel groups. All patients were divided in 2 groups by randomization: Group 1 received omeprazole at a dose of 80 mg/day, Group 2 received a combination of omeprazole and Kolofort® (a combined action drug product containing technologically processed antibodies to S100, TNF-alpha, and histamine) at a dose of 80 mg/day. At baseline and after treatment, a 10-point VAS was used to measure symptoms and an SF-36 questionnaire to evaluate the quality of life.Results. By Day 28 of the treatment, the intensity of epigastric pain (VAS score) in the group receiving proton-pump inhibitor (PPI) + Kolofort® was significantly lower. In both groups, fully resolved dyspeptic syndrome was observed in up to 90 % of patients, without significant differences (p < 0.06). According to the SF-36 data, a combination treatment resulted in higher scores (pain and general health subscales) as compared to the PPI alone.Conclusion. Kolofort® relieves symptoms and improves the quality of life when added to the treatment regimen against functional dyspepsia in post-COVID-19 patients. |
| format | Article |
| id | doaj-art-c613e7d66b744175bca0dc24d3a1eb69 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2023-05-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-c613e7d66b744175bca0dc24d3a1eb692025-02-10T16:14:37ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732023-05-01326475210.22416/1382-4376-2022-32-6-47-52513Treatment of Functional Dyspepsia in Outpatients after COVID-19 InfectionM. S. Turchina0Yu. M. Morozov1T. I. Obolenskaya2I.S. Turgenev Oryol State UniversityI.S. Turgenev Oryol State UniversityI.S. Turgenev Oryol State UniversityAim: to compare the efficacy of different therapeutic regimens for managing functional dyspepsia in outpatients after COVID-19 infection.Materials and methods. 42 post-COVID-19 outpatients (age: 26–47 years) diagnosed with functional dyspepsia (FD) according to the Rome IV Criteria were enrolled in two parallel groups. All patients were divided in 2 groups by randomization: Group 1 received omeprazole at a dose of 80 mg/day, Group 2 received a combination of omeprazole and Kolofort® (a combined action drug product containing technologically processed antibodies to S100, TNF-alpha, and histamine) at a dose of 80 mg/day. At baseline and after treatment, a 10-point VAS was used to measure symptoms and an SF-36 questionnaire to evaluate the quality of life.Results. By Day 28 of the treatment, the intensity of epigastric pain (VAS score) in the group receiving proton-pump inhibitor (PPI) + Kolofort® was significantly lower. In both groups, fully resolved dyspeptic syndrome was observed in up to 90 % of patients, without significant differences (p < 0.06). According to the SF-36 data, a combination treatment resulted in higher scores (pain and general health subscales) as compared to the PPI alone.Conclusion. Kolofort® relieves symptoms and improves the quality of life when added to the treatment regimen against functional dyspepsia in post-COVID-19 patients.https://www.gastro-j.ru/jour/article/view/780functional dyspepsiacovid-19outpatient visit |
| spellingShingle | M. S. Turchina Yu. M. Morozov T. I. Obolenskaya Treatment of Functional Dyspepsia in Outpatients after COVID-19 Infection Российский журнал гастроэнтерологии, гепатологии, колопроктологии functional dyspepsia covid-19 outpatient visit |
| title | Treatment of Functional Dyspepsia in Outpatients after COVID-19 Infection |
| title_full | Treatment of Functional Dyspepsia in Outpatients after COVID-19 Infection |
| title_fullStr | Treatment of Functional Dyspepsia in Outpatients after COVID-19 Infection |
| title_full_unstemmed | Treatment of Functional Dyspepsia in Outpatients after COVID-19 Infection |
| title_short | Treatment of Functional Dyspepsia in Outpatients after COVID-19 Infection |
| title_sort | treatment of functional dyspepsia in outpatients after covid 19 infection |
| topic | functional dyspepsia covid-19 outpatient visit |
| url | https://www.gastro-j.ru/jour/article/view/780 |
| work_keys_str_mv | AT msturchina treatmentoffunctionaldyspepsiainoutpatientsaftercovid19infection AT yummorozov treatmentoffunctionaldyspepsiainoutpatientsaftercovid19infection AT tiobolenskaya treatmentoffunctionaldyspepsiainoutpatientsaftercovid19infection |